Stephane Bancel
CIK: 0001443340
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (17 total)
- Aug 6, 2026MRNA
Moderna, Inc.
Exercise(M)Direct252.5K shares at avg. $19.15$4.8M - Aug 5, 2026MRNA
Moderna, Inc.
Exercise(M)Direct499.2K shares at avg. $19.15$9.6M - Aug 5, 2026MRNA
Moderna, Inc.
Sale(S)Direct147.5K shares at avg. $56.21$8.3M - Aug 5, 2026MRNA
Moderna, Inc.
Sale(S)Direct124.8K shares at avg. $56.96$7.1M - Aug 5, 2026MRNA
Moderna, Inc.
Sale(S)Direct39.9K shares at avg. $58.12$2.3M - Aug 5, 2026MRNA
Moderna, Inc.
Sale(S)Direct187K shares at avg. $58.79$11.0M - Mar 2, 2026GENB
Generate Biomedicines, Inc.
Conversion(C)Indirect724.2K shares- - Mar 1, 2026MRNA
Moderna, Inc.
Award(A)DirectStock Option (Right to Buy)
250.9K shares- - Feb 26, 2026GENB
Generate Biomedicines, Inc.
Award(A)DirectStock Option (Right to Buy)
29.6K shares- - Feb 11, 2026MRNA
Moderna, Inc.
Tax Payment(F)Direct5.5K shares at avg. $41.99$229K - Feb 11, 2026MRNA
Moderna, Inc.
Award(A)Direct11.3K shares- - Dec 11, 2025MRNA
Moderna, Inc.
Exercise(M)Direct688.1K shares at avg. $10.90$7.5M - Mar 3, 2025MRNA
Moderna, Inc.
Purchase(P)Indirect57.5K shares at avg. $31.53$1.8M - Mar 3, 2025MRNA
Moderna, Inc.
Purchase(P)Indirect102.8K shares at avg. $31.04$3.2M - Mar 1, 2025MRNA
Moderna, Inc.
Award(A)DirectStock Option (Right to Buy)
357.1K shares- - Feb 12, 2025MRNA
Moderna, Inc.
Tax Payment(F)Direct6.4K shares at avg. $30.93$198K - Feb 12, 2025MRNA
Moderna, Inc.
Award(A)Direct13.2K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 6, 2026 |  MRNA Moderna, Inc. | Exercise(M) | 252,469 | $19.15 | $4,834,781 | Direct |
| Aug 5, 2026 | MRNA Moderna, Inc. | Exercise(M) | 499,246 | $19.15 | $9,560,561 | Direct |
| Aug 5, 2026 | MRNA Moderna, Inc. | Sale(S) | 147,473 | $56.21 | $8,289,457 | Direct |
| Aug 5, 2026 | MRNA Moderna, Inc. | Sale(S) | 124,838 | $56.96 | $7,110,772 | Direct |
| Aug 5, 2026 | MRNA Moderna, Inc. | Sale(S) | 39,891 | $58.12 | $2,318,465 | Direct |
| Aug 5, 2026 | MRNA Moderna, Inc. | Sale(S) | 187,044 | $58.79 | $10,996,317 | Direct |
| Mar 2, 2026 |  GENB Generate Biomedicines, Inc. | Conversion(C) | 724,160 | - | $0 | Indirect |
| Mar 1, 2026 | MRNA Moderna, Inc. | Award(A) Stock Option (Right to Buy) | 250,932 | - | - | Direct |
| Feb 26, 2026 | GENB Generate Biomedicines, Inc. | Award(A) Stock Option (Right to Buy) | 29,561 | - | - | Direct |
| Feb 11, 2026 | MRNA Moderna, Inc. | Tax Payment(F) | 5,450 | $41.99 | $228,846 | Direct |
| Feb 11, 2026 | MRNA Moderna, Inc. | Award(A) | 11,271 | - | $0 | Direct |
| Dec 11, 2025 | MRNA Moderna, Inc. | Exercise(M) | 688,073 | $10.90 | $7,499,996 | Direct |
| Mar 3, 2025 | MRNA Moderna, Inc. | Purchase(P) | 57,493 | $31.53 | $1,812,754 | Indirect |
| Mar 3, 2025 | MRNA Moderna, Inc. | Purchase(P) | 102,821 | $31.04 | $3,191,564 | Indirect |
| Mar 1, 2025 | MRNA Moderna, Inc. | Award(A) Stock Option (Right to Buy) | 357,065 | - | - | Direct |
| Feb 12, 2025 | MRNA Moderna, Inc. | Tax Payment(F) | 6,400 | $30.93 | $197,952 | Direct |
| Feb 12, 2025 | MRNA Moderna, Inc. | Award(A) | 13,233 | - | - | Direct |
1-17 of 17 transactions
About Bancel Stephane
Bancel Stephane (SEC CIK 0001443340) files insider reports with the SEC as Chief Executive Officer of Moderna, Inc. (MRNA) and Director of Generate Biomedicines, Inc. (GENB).
Signal8 holds 9 ownership filings by Bancel Stephane (1 Form 3, 8 Form 4), filed between Feb 14, 2025 and Aug 7, 2026. Those filings report 17 transactions, from Feb 12, 2025 to Aug 6, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Bancel Stephane's filings is in CAMBRIDGE, MA.
Recent filings by Bancel Stephane
- Aug 6, 2026: Option exercise of MRNA shares (Form 4, code M).
- Aug 5, 2026: Option exercise of MRNA shares (Form 4, code M).
- Aug 5, 2026: Open-market sales of MRNA shares (4 lines, Form 4, code S).
- Mar 2, 2026: Conversion of GENB shares (Form 4, code C).
- Mar 1, 2026: Grant or award of MRNA derivative securities (Form 4, code A).
Other insiders filing for Moderna, Inc. (MRNA)
- Hoge Stephen, President
- Mock James M, Chief Financial Officer
- Andres Juan, Chief Operating Officer
- Klinger Shannon Thyme, Chief Legal Officer
- McDonnell Michael R., Director
- Banque Soria Ester, Chief Commercial Officer